Novartis is acquiring Avidity Biosciences for $12 billion, making it one of its largest deals. Avidity is developing RNA medicines for rare neuromuscular conditions.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Novartis to acquire Avidity in $12B bet on RNA drugs for neuromuscular disease
